Axsome Therapeutics gets grant for treating narcolepsy with cataplexy using reboxetine

19h ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Axsome Therapeutics for treating narcolepsy with cataplexy using reboxetine. Learn about the method and dosages for reducing daytime sleepiness in patients.

Axsome Therapeutics Inc AXSM

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Axsome Therapeutics Inc (AXSM) Shares Down Despite Recent Market Volatility

6d ago, source: newsheater

Axsome Therapeutics Inc (NASDAQ: AXSM) has experienced a decline in its stock price by -5.72 compared to its previous closing price of 69.71. However, the company has seen a fall of -8.38% in its ...

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

15d ago, source: Yahoo Finance

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous ...

Axsome Therapeutics Inc (AXSM) Shares Plummet Below 1-Year High

13d ago, source: newsheater

JEFFS ROGER, the Director of Axsome Therapeutics Inc, sale 2,347 shares at $71.61 during a trade that took place back on Mar 15 ’24, which means that JEFFS ROGER is holding 120,756 shares at $168,062 ...

Strong Buy on Axsome’s Auvelity Amidst Competitive MDD Market

7d ago, source:

Analyst Graig Suvannavejh of Mizuho Securities maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the ...

Axsome Therapeutics Stock (NASDAQ:AXSM), Analyst Ratings, Price Targets, Predictions

15d ago, source: Benzinga.com

$71.10 51.9% Cantor Fitzgerald ...

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

22d ago, source: Zacks.com on MSN

Axsome Therapeutics, Inc. AXSM announced that it has initiated the phase III ENGAGE study evaluating its investigational ...

Axsome Therapeutics, Inc. (AXSM)

5d ago, source: Yahoo Finance

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced the ...

Axsome Therapeutics Inc AXSM

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Axsome Therapeutics Inc (AXSM)

1mon ago, source: Investing

On Thursday, Mizuho Securities adjusted its price target for Axsome Therapeutics (NASDAQ:AXSM), a company focusing on central nervous system disorders, by a slight margin. The new ...